SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending due to a mix of factors, including a reported record demand for its $25B bond sale aimed at funding AI expansion, and discussions around Zuckerberg's hints at selling compute power. Community chatter revolves around whether the AI spending is justified and if the stock's dip presents a buying opportunity, with some citing the company's cheap valuation compared to its peers. Despite positive revenue, a one-time tax bill seems to be weighing on sentiment.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending as investors anticipate the company's earnings report, with debates swirling around potential IV crush and the impact of ad revenue performance. Community members are weighing bullish predictions against concerns of a possible pullback, influenced by Meta's recent performance. Discussions also include the potential for a Google AI deal to boost the stock.

Why Queen Kitty ($QKitty) Is The Meme Token You’ve Been Waiting For  Queen Kitty isn’t just another hype project—this is a real movement with substance and community power!  Why hold $QKitty? 😼 Real dev, real builds: No fake teams, no copy-paste code. Everything you see is made from scratch. 💧 Working Faucet: Free QKitty for the community. Want to know how? Just ask! 🏆 Big Buy Competition Bot: See top buyers live, fight for the throne, and win rewards! 🎮 Multi-token P2E game coming soon: Play and earn across Web, iOS, Android! 🐾 NFT collecting soon: Cutest collection in crypto, bringing perks and more ways to earn.  Queen Kitty means innovation, transparency, and real delivery for holders. Curious? Join the chat and ask anything!  $QKitty: By the community, for the community. To the moon, together! 🚀🐱

Queen Kitty

Queen Kitty ($QKITTY) is trending amid discussions about its upcoming DEX and SWAP features, with the community expressing excitement for potential updates and passively earning interest via its trading bot. Despite some users reporting losses, the overall sentiment is optimistic, particularly within the Solana ecosystem.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community debates the impact of recent market movements and potential catalysts. Discussions revolve around whether the current dip is a temporary setback or signals a larger shift, with some traders pointing to technical indicators and potential manipulation, while others remain optimistic about long-term fundamentals and broader institutional adoption. Traders are also monitoring macro factors like interest rate decisions and geopolitical events for their potential impact.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending downwards after earnings revealed soft traffic trends and a cautious outlook, sparking concerns about revenue and margins. The community is discussing whether this drop is an overreaction or a reflection of deeper issues with the company's value proposition amid rising costs and competition. Some believe the stock is now a buying opportunity while others worry about long-term growth.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending amid unconfirmed buyout rumors, with some traders citing a STAT News report about the company being in talks for a deal. The community is actively debating the validity of these rumors and potential acquisition prices. Some investors also point to the company's pipeline beyond COVID-19 vaccines and short squeeze potential as reasons for optimism.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as investors discuss potential catalysts from upcoming earnings, including a possible S&P 500 inclusion and buybacks. Community sentiment is mixed, with some expressing concerns about the company's correlation to Bitcoin and the impact of potential dilutions. Some traders are anticipating volatility post-earnings, while others believe the stock is oversold and due for a bounce.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors react to strong earnings, highlighting growth in cloud services and advertising revenue, with particular attention to the company's AI initiatives. The community is debating whether the stock's recent surge has priced in future growth, while analysts are raising price targets and citing Google's leadership in AI. Some traders are expressing concern about the run-up into earnings, while others are locking in profits or betting on continued upside.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending amid discussions of a potential short squeeze and positive financial outlook, including raised EBITDA guidance for 2025. Community members are actively debating price targets and the possibility of a significant rally, citing the company's low PE ratio and potential for multiple expansion. Some are attributing the stock's movement to broader trends in the bio sector and optimism surrounding future earnings reports.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as community members discuss the potential for a short squeeze, driven by high short interest and optimism around the company's pipeline. Chatter revolves around buyout speculation, comparisons to competitors, and anticipation for upcoming presentations at ObesityWeek. The stock's recent performance and market dynamics in the obesity treatment sector are also fueling the conversation.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy

Does Alto Neuroscience, Inc. (ANRO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Can Alto Neuroscience, Inc. (ANRO) Climb 27.45% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 27.5% upside potential for Alto Neuroscience, Inc. (ANRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Shares of Alto Neuroscience (ANRO) soared 54% on Friday afternoon after the company announced that the U.S. Food and Drug Administration granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.Cognitive impairment is a core and disabling feature of Schizophrenia, a serious, disabling mental illness affecting thought, perception, and behavior. According to Alto, there are currently no approved treatments for cognitive impairment associated with schizophrenia.FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. A company, whose drug has a Fast Track designation, may be eligible for more frequent meetings with the FDA to discuss the drug’s development plan, as well as for accelerated approval and priority review, subject to the fulfillment of relevant criteria.ALTO-101 is an inhibitor of the PDE4 enzyme that plays a key role in the brain by breaking down a molecule fundamental to learning and memory. By inhibiting the enzyme, the drug seeks to increase the levels of the molecule believed to improve cognitive function.Alto CEO Amit Etkin <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.altoneuroscience.com/news/news-details/2025/Alto-Neuroscience-Receives-FDA-Fast-Track-Designation-for-ALTO-101-for-the-Treatment-of-Cognitive-Impairment-Associated-with-Schizophrenia/default.aspx">termed</a> the designation a significant milestone. “Our Phase 1 data, which demonstrated significant and clinically relevant effects of ALTO-101 on both EEG measures and cognitive performance in healthy subjects, provides strong validation for its mechanism,” he added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANRO">ANRO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:579/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_01_14_PM_png_f2a3fffa4a.webp" alt="ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="579" height="59"><figcaption>ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user highlighted the company’s strong pipeline. Alto is seeking to develop treatments for mental health conditions, including bipolar depression, major depressive disorder, treatment-resistant depression (TRD), and schizophrenia.<stembedurl>https://stocktwits.com/Ccperk/message/630959482</stembedurl>Another user believes the FDA's Fast Track designation is the icing on the cake.<stembedurl>https://stocktwits.com/Ccperk/message/630949029</stembedurl>ANRO stock is up by 61% this year but down by 33% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-reportedly-eyes-door-redesign-to-alleviate-safety-concerns-report/chCuVXzR3QQ">Rivian Reportedly Eyes Door Redesign To Alleviate Safety Concerns: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

Equity

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.


Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO

Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO Alto Neuroscience, Inc. Sued for Securities Law Violations...

1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March

Alto Neuroscience represents a high-risk, high-reward opportunity.

Alto Neuroscience Inc. has struggled recently, with shares losing more than 12% over the past week, extending a decline that began in late October following disappointing Phase 2&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anro-stock-crashes-premarket-after-drug-trial-fails/cJ2L0NwReH">results</a> for its major depressive disorder (MDD) treatment, ALTO-100.&nbsp;Despite the stock sliding over 34% this year, it has not lost appeal among retail traders as Alto's follower count on Stocktwits has surged 44.6% in the past week.&nbsp;Over the last year, its retail following on the platform has grown by an astonishing 876%, suggesting that traders remain interested in the company's long-term prospects.Alto is developing treatments for central nervous system diseases and has positioned its biomarker-driven approach as a differentiator in psychiatric drug development.&nbsp;While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.&nbsp;Last month, Alto announced that a planned interim analysis of the trial had a favorable outcome, prompting the company to expand the study by approximately 50 biomarker-positive patients. Topline results from the trial are expected in mid-2026.&nbsp;The company also secured a U.S. patent for ALTO-300, covering its use as an adjunctive treatment for MDD patients who have not responded adequately to traditional antidepressants.&nbsp;The patent also includes methods for identifying eligible patients using EEG-based biomarker selection, which Alto sees as a key advantage in developing more targeted psychiatric treatments.<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ANRO_sentiment_and_message_volume_as_of_Feb_28_3028c3e1a2.png" alt="ANRO sentiment and message volume as of Feb 28.png" width="1316" height="316"><figcaption>ANRO sentiment and message volume as of Feb 28 vs a week ago | source: Stocktwits</figcaption></figure>Retail traders on Stocktwits have pointed to several potential catalysts, including reports that Jefferies sees a 500% upside for the stock.&nbsp;Some investors have also highlighted Alto's financial position, noting that the company is trading near 40% of its cash value while holding two Phase 3-ready assets and no debt.<stembedurl>https://stocktwits.com/Eternallybullish1988/message/606427653</stembedurl><stembedurl>https://stocktwits.com/BossTrade/message/606325236</stembedurl>Jones Research maintained a 'Buy' rating with an $18 price target in December, arguing that the market reaction to ALTO-100's failure was overdone.&nbsp;Last week, Alto said it would participate in a series of upcoming industry conferences in March, including the TD Cowen 45th Annual Health Care Conference, Leerink's Global Healthcare Conference, and the Stifel 2025 Virtual CNS Forum.&nbsp;With attention now focused on the ALTO-300 trial and upcoming investor events, retail investors will be hoping market sentiment around the stock tilts back into the bullish zone.Alto stock is rated ‘buy’ among six out of seven analysts covering the stock on Wall Street, with one rating ‘hold’, according to Koyfin data.Short interest, meanwhile, has edged down from 15.1% at the start of this year to 14.7% as of the end of last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock

While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 

Why Micro-Cap Alto Neuroscience's Retail Following On Stocktwits Surged Nearly 45% Last Week

While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 


Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the...

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple...

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.67	--	--	N/A
Q2 '25	-$0.60	-$0.65	-8.58%	MISSED
Q1 '25	-$0.61	-$0.56	7.98%	BEAT
Q4 '24	-$0.65	-$0.52	19.47%	BEAT
Q3 '24	-$0.65	-$0.62	4.62%	BEAT

ANRO
Alto Neuroscience Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ANRO News

ANROAlto Neuroscience Inc.